Antiproliferative activity from Aldama arenaria (Baker) E. E. Schill. & Panero | Zendy

Adriana da Silva Santos de Oliveira | Zendy; Paulo M. Imamura | Zendy; Ana Lúcia Tasca Góis Ruiz | Zendy; Beatriz AppezzatodaGlória | Zendy; Tuane de Oliveira | Zendy; Vera Lúcia Garcia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiproliferative activity from Aldama arenaria (Baker) E. E. Schill. & Panero

Author(s) -

Adriana da Silva Santos de Oliveira,

Paulo M. Imamura,

Ana Lúcia Tasca Góis Ruiz,

Beatriz AppezzatodaGlória,

Tuane de Oliveira,

Vera Lúcia Garcia

Publication year - 2020

Publication title -

boletin latinoamericano y del caribe de plantas medicinales y aromaticas

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.218

H-Index - 21

ISSN - 0717-7917

DOI - 10.37360/blacpma.21.20.1.4

Subject(s) - in vitro , melanoma , ovary , chemistry , cancer research , pharmacology , medicine , biology , biochemistry

Chloroform extract (CE) and fractions obtained from Aldama arenaria roots were evaluated for their in vitro antiproliferative activity against 10 human tumor cell lines [leukemia (K-562), breast (MCF-7), ovary expressing a multidrug-resistant phenotype (NCI/ADR-RES), melanoma (UACC-62), lung (NCI-H460), prostate (PC-3), colon (HT29), ovary (OVCAR-3), glioma (U251), and kidney (786-0)]. CE presented weak to moderate antiproliferative activity (mean log GI50 1.07), whereas fractions 3 and 4, enriched with pimarane-type diterpenes [ent-pimara-8(14),15-dien-19-oic acid and ent-8(14),15-pimaradien-3β-ol], presented moderate to potent activity for most cell lines, with mean log GI50 of 0.62 and 0.59, respectively. The results showed promising in vitro antiproliferative action of the samples obtained from A. arenaria, with the best results for NCI/ADR-RES, HT29, and OVCAR-3, and TGI values ranging from 5.95 to 28.71 µg.mL-1, demonstrating that compounds of this class may be potential prototypes for the discovery of new therapeutic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research